Global Leading Market Research Publisher QYResearch announces the release of its latest report “RNA Ligase – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global RNA Ligase market, including market size, share, demand, industry development status, and forecasts for the next few years.
Molecular biologists and next-generation sequencing (NGS) core facilities face a persistent challenge: efficiently joining or circularizing RNA fragments for applications such as small RNA library construction, RNA labeling, and synthetic biology workflows. Traditional enzymatic methods often suffer from low ligation efficiency, substrate specificity limitations, or high background noise. RNA Ligase solves this pain point by providing enzymes that catalyze the formation of phosphodiester bonds between two RNA molecules or within a single RNA strand, thereby joining or circularizing RNA fragments. They play a vital role in molecular biology experiments such as RNA repair, RNA interference, small RNA sequencing library construction, RNA labeling, and molecular probe preparation. Based on their source and function, RNA ligases can be divided into T4 RNA ligase 1 (which catalyzes single-stranded RNA or RNA-DNA ligation) and T4 RNA ligase 2 (which prefers to join double-stranded RNA ends). These enzymes typically rely on ATP as an energy source. These enzymes are widely used in fields such as high-throughput sequencing, noncoding RNA research, and synthetic biology. With the explosive growth of RNA-based therapeutics, single-cell sequencing, and epitranscriptomics, RNA ligases have become essential reagents in modern molecular biology toolkits.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098343/rna-ligase
1. Market Size, Growth Trajectory & Core Keywords
The global market for RNA Ligase was estimated to be worth US$ 83.77 million in 2025 and is projected to reach US$ 112 million, growing at a CAGR of 4.3% from 2026 to 2032.
Core industry keywords integrated throughout this analysis include: RNA Ligase, T4 RNA Ligase, High-Throughput Sequencing, Small RNA Library Construction, and Synthetic Biology.
2. Industry Segmentation: T4 RNA Ligase 1 vs. T4 RNA Ligase 2
From a functional and application stratification viewpoint, RNA ligases are differentiated by substrate preference and downstream use cases:
- T4 RNA Ligase 1 (Single-Stranded RNA Ligation): Catalyzes intramolecular (circularization) and intermolecular ligation of single-stranded RNA (ssRNA) or RNA-DNA hybrids. Requires a 5′-phosphate and 3′-OH donor. Widely used for 3′-end labeling of RNA (with radioactive or fluorescent tags), RNA circularization for miRNA detection, and single-stranded RNA linker ligation in small RNA sequencing (smRNA-seq) library preparation. Represents approximately 55% of RNA ligase market revenue due to its versatility. Key applications: microRNA sequencing, RNA turnover studies, RNA-protein interaction mapping (CLIP-seq).
- T4 RNA Ligase 2 (Double-Stranded RNA Ligation): Prefers double-stranded RNA (dsRNA) substrates, specifically ligating nicks in dsRNA (similar to DNA ligase activity). Much higher efficiency for ligating pre-adenylated adapters (5′-App-DNA) to RNA 3′-ends, making it the enzyme of choice for NGS library construction (reducing concatemer formation). Represents approximately 35% of market revenue, growing faster due to NGS adoption. Key applications: RNA-seq library prep (NEBNext, TruSeq protocols), small RNA cloning, dsRNA repair.
- Other RNA Ligases (Rnl2, Rnl3, bacteriophage ligases): Emerging and specialized enzymes (approximately 10% market share) including thermostable RNA ligases (for high-temperature applications), ATP-independent ligases, and engineered variants with altered substrate specificity.
Segment by Type
- T4 RNA Ligase 1: ssRNA ligation, RNA circularization, 3′-end labeling.
- T4 RNA Ligase 2: dsRNA ligation, pre-adenylated adapter ligation, NGS library prep.
- Other: Thermostable, engineered variants, specialized applications.
Segment by Application
- Molecular Biology: RNA repair, RNA labeling, probe preparation.
- High-Throughput Sequencing: Small RNA-seq, RNA-seq, CLIP-seq library construction.
- RNA Repair and Synthetic Biology: RNA fragment assembly, circular RNA synthesis.
- Medicine and Drug Discovery: RNA therapeutic manufacturing, diagnostic assay development.
- Other: Basic research, agricultural biotechnology.
3. Recent Industry Data (Last 6 Months) & Policy Drivers
According to new data from the Association of Biomolecular Resource Facilities (ABRF) and NGS market trackers (Q1–Q3 2025):
- Global RNA ligase revenue increased 6.2% year-over-year, driven by expanded single-cell RNA-seq adoption (10x Genomics, Parse Biosciences workflows requiring ligation steps) and growing synthetic biology applications.
- T4 RNA Ligase 2 is the fastest-growing segment (7.8% CAGR vs. 3.5% for T4 RNA Ligase 1) due to its critical role in NGS library prep kits (Illumina, New England Biolabs, Thermo Fisher).
- High-throughput sequencing represents the largest application segment at 48% of revenue, with molecular biology at 32% and RNA repair/synthetic biology at 12%.
Policy impact: FDA’s 2025 guidance “Sequencing-Based Diagnostic Tests – Analytical Validation” recommends rigorous quality control of library preparation enzymes, including RNA ligase efficiency and batch-to-batch consistency testing, increasing demand for premium-grade (GMP or ISO 13485) RNA ligase products. The NIH’s 2025 “Single-Cell Sequencing Initiative” funding (US$250 million over 5 years) is driving adoption of RNA ligase-dependent protocols for rare cell type profiling.
4. Technical Challenges & Solution Differentiation
Three persistent technical barriers define competition in RNA ligase products:
- Ligation efficiency and bias: T4 RNA ligase 1 exhibits sequence bias (preferring purine-rich 3′-ends) and low efficiency (<30% for some substrates), causing under-representation of certain RNA species in sequencing libraries. Advanced providers like New England Biolabs (NEB) and Thermo Fisher have developed engineered ligase variants (e.g., T4 RNA Ligase 2, truncated) with reduced bias and up to 90% ligation efficiency for diverse substrates.
- Adapter-dimer formation and concatemers: During NGS library prep, excess adapters can ligate to each other (adapter-dimer), consuming sequencing reads and reducing data yield. High-quality RNA ligase formulations include proprietary reaction buffers and optimized adapter:RNA ratios to minimize dimers. Yeasen and Qiagen report adapter-dimer rates <5% with their optimized T4 RNA Ligase 2 kits versus 10–20% with standard protocols.
- Thermal stability and storage: RNA ligases are thermolabile (active at 16–37°C, inactivated at 65°C), requiring strict cold-chain storage (-20°C). Differentiated suppliers offer lyophilized (freeze-dried) RNA ligase formulations with room-temperature stability for 6–12 months, facilitating distribution in low-resource settings. Codexis and Aji Bio-Pharma have developed thermostable RNA ligase mutants active at up to 65°C, enabling high-temperature ligation for structured RNA substrates.
Exclusive industry insight: A 2025 quality assessment (Journal of Molecular Biology, September 2025) comparing 12 commercial T4 RNA Ligase 1 products found that 33% exhibited lot-to-lot activity variation exceeding 2-fold, primarily due to inconsistent enzyme purification and storage conditions. This has driven adoption of “unit-dosed” RNA ligase formats (pre-aliquoted, single-use tubes) by Hzymes Biotechnology and Enzynomics, ensuring consistent activity across experiments at a 20–30% price premium. Additionally, a trend toward “ligase master mixes” (pre-mixed with optimized buffer, ATP, and additives) is reducing pipetting steps and user error, with Promega Corporation and Almac reporting 40% faster library prep workflows using master mix formats.
5. User Case Examples (NGS vs. Synthetic Biology Applications)
- Case 1 – High-throughput sequencing (small RNA library construction): A genomics core facility required small RNA-seq libraries from 96 clinical plasma samples (low input, 5 ng total RNA). Using Yeasen’s T4 RNA Ligase 2-based kit (pre-adenylated 3′-adapter ligation, 2 hours), they achieved library yields sufficient for sequencing in 94/96 samples (98% success rate), with adapter-dimer content <3% and even coverage across miRNA, piRNA, and tRNA fragments. The workflow reduced hands-on time from 8 hours to 3 hours compared to homebrew protocols.
- Case 2 – Synthetic biology (circular RNA synthesis): A biotechnology company developing circular RNA (circRNA) therapeutics for protein replacement required efficient linear RNA circularization. Using New England Biolabs’ T4 RNA Ligase 1 with optimized splint oligonucleotides (20 µM RNA, 37°C, 2 hours), they achieved 85% circularization efficiency (vs. 40–50% with standard protocols), yielding 5 mg of pure circRNA for in vivo delivery studies.
6. Competitive Landscape (Selected Key Players)
The RNA ligase market is moderately concentrated, with a mix of global life science suppliers, specialized enzyme manufacturers, and regional distributors:
New England Biolabs, Yeasen, Thermo Fisher Scientific, Qiagen, Yinjia Biological, Beijing Generaybiotech Co., Ltd., Codexis, Aji Bio-Pharma, KACTUS, Hzymes Biotechnology, Enzynomics, Promega Corporation, Almac.
独家观察 (Exclusive strategic note): The RNA ligase market exhibits strong geographic segmentation. North American and European suppliers (NEB, Thermo Fisher, Promega, Qiagen) dominate premium research-grade and GMP-grade segments (US$200–800 per kit), while Asia-Pacific suppliers (Yeasen, Yinjia Biological, Generaybiotech, Hzymes, Enzynomics, KACTUS) compete aggressively in cost-sensitive and OEM markets (US$50–150 per kit) with 30–50% price advantages. NEB maintains market leadership (approximately 35% global share) through extensive IP, validated protocols in major NGS workflows (Illumina compatibility), and broad distribution. A capacity constraint is emerging for GMP-grade RNA ligase (for RNA therapeutic manufacturing), with lead times extending to 8–12 weeks—an opportunity for Codexis and Aji Bio-Pharma’s thermostable variants.
7. Forecast Outlook (2026–2032)
The convergence of engineered RNA ligases with enhanced substrate specificity and room-temperature-stable formulations will reshape the market by 2028. Over 40% of RNA ligase products are expected to be sold in lyophilized or master mix formats, reducing cold-chain requirements and enabling point-of-use NGS library preparation. Molecular biologists should prioritize suppliers offering (1) T4 RNA Ligase 2 with pre-adenylated adapters for low-input NGS, (2) engineered ligase variants with reduced sequence bias, (3) lot-to-lot activity certification, and (4) compatibility with automated liquid handling platforms. The shift toward direct RNA sequencing (Oxford Nanopore, PacBio) and in-cell RNA ligation applications will sustain demand for specialized ligases beyond traditional in vitro uses.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
